Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Neoplasm Metastasis 8Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Ovarian Neoplasms 5Melanoma 5Carcinoma, Renal Cell 5Skin Neoplasms 4Fallopian Tube Neoplasms 4Carcinoma 4Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Mouth Neoplasms 3Colorectal Neoplasms 3Breast Neoplasms 3Adenocarcinoma 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Endometrial Neoplasms 2

Interventions

Cyclophosphamide 2sodium-iodide symporter 1ruxolitinib 1glofitamab 1fludarabine 1duvelisib 1cemiplimab 1belinostat 1X-Rays 1Specimen Handling 1Positron-Emission Tomography 1Photons 1Nivolumab 1Magnetic Resonance Spectroscopy 1MAC-ST-001 1Immunoglobulin G 1Gemcitabine 1Fenretinide 1Disulfides 1Biopsy 1Bendamustine Hydrochloride 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Immunoblastic Lymphadenopathy × cemiplimab × Clear all
NCT03017820 2026-06-10

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
99 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡